Dipeptide Peptidase 4 Inhibitors Market Report 2026

The dipeptide peptidase 4 inhibitors market size has grown steadily in recent years. It will grow from $11.81 billion in 2025 to $12.39 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to growing prevalence of type 2 diabetes globally, need for glucose-lowering therapies with low hypoglycemia risk, widespread clinical acceptance of incretin-based therapies, availability of multiple branded dpp-4 inhibitors, expansion of outpatient diabetes management.

The dipeptide peptidase 4 inhibitors market size is expected to see steady growth in the next few years. It will grow to $14.78 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to rising global diabetic population, increasing adoption of combination diabetes therapies, growing focus on patient-friendly oral treatments, expanding access to diabetes care in emerging markets, continued demand for cost-effective glycemic control options. Major trends in the forecast period include sustained use of dpp-4 inhibitors as add-on therapy in type 2 diabetes, growing preference for oral antidiabetic medications, increasing use of dpp-4 inhibitors in elderly diabetic patients, rising demand for fixed-dose combination therapies, steady shift toward generic dpp-4 inhibitor formulations.

The rising prevalence of diabetes is expected to propel the growth of the dipeptidyl peptidase-4 inhibitors market in the coming years. Diabetes is a long-term condition that affects the body’s ability to regulate and utilize glucose, an essential source of energy for cells. The increasing burden of diabetes is largely attributed to the widespread adoption of sedentary lifestyles and unhealthy dietary habits in modern populations. Dipeptidyl peptidase-4 inhibitors are used in the management of diabetes to enhance glycemic control by inhibiting the degradation of incretin hormones. For instance, in 2024, according to the International Diabetes Federation, a Belgium-based health organization, an estimated 537 million adults worldwide are living with diabetes, with the number projected to reach 643 million by 2030 and 783 million by 2045. Therefore, the growing prevalence of diabetes is driving the expansion of the dipeptidyl peptidase-4 inhibitors market.

The increasing number of government initiatives for diabetes management is expected to drive the growth of the dipeptidyl peptidase-4 inhibitors market in the coming years. Government initiatives include programs, policies, and actions implemented by authorities at local, regional, national, or international levels to address specific challenges, enhance public welfare, or achieve defined objectives. The rise in government initiatives focused on diabetes management is largely attributed to the growing economic burden of the disease, the need to improve health equity, and increasing concerns regarding effective health management. These initiatives play a crucial role in supporting the development of dipeptidyl peptidase-4 inhibitors by promoting healthcare infrastructure, ensuring patient access to treatments, encouraging innovation, and increasing investment in drug development. For example, in 2023, according to the Australian Government Department of Health, an Australia-based government agency, the government launched the Australian National Diabetes Strategy 2021-2030. This strategy highlights the importance of diabetes prevention, early detection, and effective management, and aligns with global frameworks such as the Global Action Plan for the Prevention and Control of Non-Communicable Diseases and the WHO Global Diabetes Compact. Consequently, the growth in government initiatives for diabetes management is fueling the expansion of the dipeptidyl peptidase-4 inhibitors market.

In August 2023, Lupin, an India-based pharmaceutical company, acquired two diabetes brands, ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH for an undisclosed amount. This acquisition is intended to strengthen Lupin’s commitment to offering improved treatment options for diabetes patients and to expand its portfolio in the anti-diabetes segment. Boehringer Ingelheim International GmbH is a Germany-based pharmaceutical company that manufactures dipeptidyl peptidase-4 (DPP-4) inhibitors.

Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy's Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd.

Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dipeptide peptidase 4 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the DPP-4 inhibitors market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation excipients used in oral antidiabetic drugs. These impacts have been most noticeable in branded DPP-4 inhibitor segments across North America and Europe, where API sourcing is globally diversified. Asia-Pacific manufacturers have faced pricing pressures due to cross-border trade dependencies. However, tariffs have encouraged local API production and domestic manufacturing of generic DPP-4 inhibitors, supporting supply security and competitive pricing.

The dipeptide peptidase 4 inhibitors market research report is one of a series of new reports that provides dipeptide peptidase 4 inhibitors market statistics, including dipeptide peptidase 4 inhibitors industry global market size, regional shares, competitors with a dipeptide peptidase 4 inhibitors market share, detailed dipeptide peptidase 4 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the dipeptide peptidase 4 inhibitors industry. This dipeptide peptidase 4 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a group of medications used to treat type 2 diabetes by increasing the levels of active incretin hormones to help control blood glucose. These drugs function by enhancing incretin activity, which promotes insulin secretion and suppresses glucagon release, leading to reduced blood sugar levels.

The primary dipeptidyl peptidase-4 inhibitors include sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin, and others. Sitagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes by helping regulate blood glucose levels. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online platforms. It is used for conditions such as type 2 diabetes, gestational diabetes, metabolic syndrome, and others.

The dipeptidyl peptidase-4 inhibitors market consists of sales of gemigliptin, anagliptin, teneligliptin and trelagliptin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.